B A C K G R O U N D Description of the condition
Lung transplantation is potentially the only life-prolonging treatment available for end-stage chronic lung disease. However, despite significant advances in recipient selection, surgical technique, and immunosuppressant therapy, which have led to improvements in survival, the median survival remains poorer than other solid organ transplants at 5.7 years (ISHLT Report 2015). Bronchiolitis obliterans syndrome (BOS) is a major subtype of the recently termed Chronic Lung Allograft Dysfunction (CLAD) or late graft failure after lung transplantation. BOS is estimated to develop in 50% of adult lung transplant recipients within 5 years of transplantation and in 76% by 10 years (ISHLT Report 2015), and was the most common indication for adult lung re-transplantation during January 1995 to June 2013 (ISHLT Report 2014), internationally.
As defined by the International Society for Heart and Lung Transplantation (ISHLT) guidelines, BOS is a delayed allograft dysfunction, characterised by a persistent (more than three weeks) obstructive lung function with a decline in forced expiratory volume in one second (FEV 1 ), which is not caused by other known and potentially reversible causes of post-transplant loss of lung function (Meyer 2014). Obliterative bronchiolitis (OB) is the hallmark of BOS on histopathology (Verleden 2014), although, it is difficult to diagnose on transbronchial lung biopsy, the most commonly used biopsy method in clinical practice. BOS is graded according to the severity of FEV 1 
Description of the intervention
Currently there is no gold standard treatment for BOS; this has resulted in a range of therapies being tried, which have included switching immunosuppressants, total lymphoid irradiation ( 
How the intervention might work
Azithromycin is currently hypothesised to primarily impact BOS via its immunomodulatory and anti-inflammatory pathway (Vos 2012 
Why it is important to do this review
BOS is the Achilles heel of lung transplantation; it is the major cause of late graft failure after lung transplantation and mortality. Therapeutic approaches for BOS have ranged from switching immunosuppression to total lymphoid irradiation, which have had variable and modest impact on the rate of decline in graft function in BOS ( 
O B J E C T I V E S
This review aims to look at the benefits and harms of azithromycin for the treatment of BOS in adult lung transplant recipients.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All RCTs and quasi-RCTs (RCTs in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth or other predictable methods) looking at azithromycin for BOS in adult lung transplant recipients.
Types of participants
Adult lung transplant recipients, both male and female, who have been diagnosed with BOS, as per 2001 criteria (Estenne 2002), will be included.
Inclusion criteria
• Lung transplant recipients, including single lung, double lung, re-do transplants, and heart and lung transplant recipients.
• Male and female patients.
• Age 18 years and over.
Exclusion criteria
• Lung transplant recipients under the 18 years of age will be excluded as azithromycin has not been established for treatment of BOS in the paediatric lung transplant recipient cohort.
Types of interventions
• We will compare the daily dosing regimen to three times a week regimen.
• We will compare long term (eight weeks and more) oral azithromycin therapy, 250 mg three times/week and 500 mg three times/week, to:
• Placebo
Azithromycin in capsule, tablet, and oral suspension formulation is accepted. It is expected for the patients diagnosed with BOS to receive high dose intravenous methylprednisolone followed by a tapering course of oral steroids, and optimisation of immunosuppressant therapy, as standard treatment. 
Types of outcome measures

Data collection and analysis
Selection of studies
The search strategy described will be used to obtain titles and abstracts of studies that may be relevant to the review. The titles and abstracts will be screened independently by two authors, who will discard studies that are not applicable; however, studies and reviews that might include relevant data or information on trials will be retained initially. Two authors will independently assess retrieved abstracts and, if necessary the full text, of these studies to determine which studies satisfy the inclusion criteria. Any disagreements will be resolved by discussion, and, if necessary, arbitration by the third or fourth author.
Data extraction and management
Data extraction will be carried out independently by two authors using standard data extraction forms. Studies reported in nonEnglish language journals will be translated before assessment. Where more than one publication of one study exists, reports will be grouped together and the publication with the most complete data will be used in the analyses. Where relevant outcomes are only published in earlier versions these data will be used. Any discrepancy between published versions will be highlighted.
Assessment of risk of bias in included studies
The following items will be independently assessed by two authors using the risk of bias assessment tool (Higgins 2011) (see Appendix 2).
• Was there adequate sequence generation (selection bias)?
• Was allocation adequately concealed (selection bias)?
• Was knowledge of the allocated interventions adequately prevented during the study?
• Participants and personnel (performance bias)
• Outcome assessors (detection bias) • Were incomplete outcome data adequately addressed (attrition bias)?
• Are reports of the study free of suggestion of selective outcome reporting (reporting bias)?
• Was the study apparently free of other problems that could put it at a risk of bias?
Measures of treatment effect
For dichotomous outcomes (reversal of BOS, halted progression of BOS, progression to next BOS stage, re-transplantation, and death) results will be expressed as risk ratio (RR) with 95% confidence intervals (CI). Where continuous scales of measurement are used to assess the effects of treatment (FEV 1 ), the mean difference (MD) will be used, or the standardised mean difference (SMD) if different scales have been used. Where death or re-transplantation are reported as a time to event data, these will be analysed as per the Cochrane Handbook, using summary statistics from individual trial reports. If estimates of log hazard ratios and standard errors are available from Cox proportional hazards are available, these will be analysed by the generic inverse-variance method. If O-E and variance data, or if log rank methods are reported, these will be analysed with Peto's method. If standard deviations of changes from baseline (such as for FEV 1 ) are missing, these will be calculated if other information (such as P values) are available. If this is not possible, we will impute standard deviations using the methods from the Cochrane Handbook Chapter 16.
Unit of analysis issues
For cross-over studies, where possible, we will use the first treatment cycle prior to the 'cross-over', to avoid the effect of treatment 'hangover'. Where multiple groups are investigated in one study, we will use each group only once in meta-analysis, to remove the impact of unit of analysis issues. Where possible, we will combine groups to make a single pair-wise comparison. Other approaches which will be taken are (i) removing interventions not relevant to this review, (ii) splitting a shared group into multiple groups and including these in the meta-analysis or (iii) including correlated comparisons, and using appropriate methods for accounting with the correlation.
Dealing with missing data
Any further information required from the original author will be requested by written correspondence (e.g. emailing corresponding authors) and any relevant information obtained in this manner will be included in the review. Evaluation of important numerical data such as screened, randomised patients as well as intentionto-treat, as-treated and per-protocol population will be carefully performed. Attrition rates, for example drop-outs, losses to followup and withdrawals will be investigated. Issues of missing data and imputation methods (for example, last-observation-carriedforward) will be critically appraised (Higgins 2011).
Assessment of heterogeneity
We will first assess the heterogeneity by visual inspection of the forest plot. Heterogeneity will then be analysed using a Chi 2 test on N-1 degrees of freedom, with an alpha of 0.05 used for statistical significance and with the I 2 test (Higgins 2003) . A guide to the interpretation of I 2 values will be as follows:
• 0% to 40%: might not be important • 30% to 60%: may represent moderate heterogeneity • 50% to 90%: may represent substantial heterogeneity • 75% to 100%: considerable heterogeneity.
The importance of the observed value of I 2 depends on the magnitude and direction of treatment effects and the strength of evidence for heterogeneity (e.g. P-value from the Chi 2 test, or a CI for I 2 ) (Higgins 2011).
Assessment of reporting biases
If possible, funnel plots will be used to assess for the potential existence of publication bias (Higgins 2011).
Data synthesis
Data will be pooled using the random-effects model but the fixedeffect model will also be used to ensure robustness of the model chosen and susceptibility to outliers.
Subgroup analysis and investigation of heterogeneity
Subgroup analysis will be used to explore possible sources of heterogeneity (e.g. studies with or without blinding). Heterogeneity among participants could be related to the type of transplant (e.g. single versus double versus heart-lung transplant). Heterogeneity in treatments could be related to prior agent(s) used and the dose and duration of therapy (e.g. azithromycin 250 mg versus 500 mg). Adverse effects will be tabulated and assessed with descriptive techniques. Where possible, the risk difference with 95% CI will be calculated for each adverse effect, either compared to no treatment or to another agent.
Sensitivity analysis
We will perform sensitivity analyses in order to explore the influence of the following factors on effect size.
• Repeating the analysis excluding unpublished studies • Repeating the analysis taking account of risk of bias, as specified
• Repeating the analysis excluding any very long or large studies to establish how much they dominate the results
• Repeating the analysis excluding studies using the following filters: diagnostic criteria, language of publication, source of funding (industry versus other), and country
• Repeating the analysis excluding quasi-RCTs.
'Summary of findings' tables
We will present the main results of the review in 'Summary of findings' tables. These tables present key information concerning the quality of the evidence, the magnitude of the effects of the interventions examined, and the sum of the available data for the main outcomes (Schunemann 2011a). The 'Summary of findings' tables also include an overall grading of the evidence related to each of the main outcomes using the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) approach (GRADE 2008) . The GRADE approach defines the quality of a body of evidence as the extent to which one can be confident that an estimate of effect or association is close to the true quantity of specific interest. The quality of a body of evidence involves consideration of within-trial risk of bias (methodological quality), directness of evidence, heterogeneity, precision of effect estimates and risk of publication bias (Schunemann 2011b). We plan to present the following outcomes in the 'Summary of findings' tables.
• Lung function improvement, defined as ≥ 10% improvement in FEV 1 • Proportion of patients progressing to BOS stage 3 • Decision to re-transplant • Survival • Adverse events, including hearing impairment, cardiac dysrhythmias, prolonged QT interval on ECG, and hepatotoxicity.
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